Primary outcome results for hydroxychloroquine prophylaxis randomized controlled trials.

Table 2: Primary outcome results for hydroxychloroquine prophylaxis randomized controlled trials.

Study	N	Outcome	Control			HCQ		Relative risk¹ (95% CI)	Absolute risk difference¹ (95% CI)
Study	N	Outcome	n	event		n	event	Relative risk¹ (95% CI)	Absolute risk difference¹ (95% CI)
Pre exposure prophylaxis
Abella, et al. [19]	125	PCR confirmed COVID-19	61	4		64	4	0.95 (0.25, 3.64)	-0.3% (-8.9%, 8.3%)
Rajasingham, et al. [18]	1483	PCR confirmed or probable COVID-19	494	39		989	58	0.74 (0.50, 1.10)	-2.0% (-4.8%, 0.8%)
Post exposure prophylaxis
Mitja, et al. [17]	2134	PCR confirmed symptomatic COVID-19	1198	64	1116		74	0.89 (0.54, 1.46)	-0.6% (-2.5%, 2.5%)
Boulware, et al. [16]	821	PCR confirmed or probable COVID-19	407	58	414		49	0.83 (0.58, 1.18)	-2.4% (-7.0%, 2.2%)

HCQ: Hydroxychloroquine; PCR: Polymerase Chain Reaction; Abella, et al. [19]: Treatment effects are presented for hydroxychloroquine compared to control arm; Rajasingham, et al. [18]: Rajasingham results are presented for pooled hydroxychloroquine arms; Mitja, et al. [17]: Risk differences for Mitja are calculated relative to event rate in control arm using reported relative risks to account for cluster study design.